Dr. Michelle M. Inserra, MD

Dr. Inserra practices at BASS Imaging Center - Walnut Creek in Walnut Creek, California.

Dr. Inserra's NPI, 1356428205, was assigned on October 31, 2006. Dr. Inserra graduated from Stanford University School Of Medicine in 1999. Dr. Inserra's California license number on file is A73027.

Dr. Inserra's primary practice is BASS Imaging Center - Walnut Creek, at 2637 Shadelands Drive, Walnut Creek, CA 94598. The practice phone is (925) 329-3710.

Dr. Inserra's primary practice is BASS Imaging Center - Walnut Creek in Walnut Creek, California. Dr. Inserra is also affiliated with El Camino Health - Mountain View Hospital. The medical group on file is BASS Medical Group. Dmand AI also links Dr. Inserra to 1 more group practice or clinic, named with a free account. Dr. Inserra's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Inserra practices, 3 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Inserra's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Inserra is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dr. Inserra has a license on file in California.

Dmand AI lists ear eustachian tube disorders, ear infection, hearing loss and impairment, swimmer's ear, tinnitus and vertigo among the conditions Dr. Inserra treats.

CMS data shows 674 Medicare services from Dr. Inserra across 10 procedure codes in 2024, for 278 Medicare patients. Medicare paid $50,266 for them. Every service was in an office.

CMS counts 278 Medicare patients who saw Dr. Inserra in 2024. The largest group is 75 to 84, with 125 patients. 75% of them have high cholesterol, and 69% have high blood pressure. Their average risk score is 0.97, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Inserra's median patient age at 63, with 61% women.

In 2024, Dr. Inserra wrote 265 Medicare Part D claims for 114 patients. 93% of them were for generic drugs. CMS names the drug for 171 of them, across 9 drugs with 11 or more claims each, at $23,009 in total drug cost. In 2023, CMS named 185 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Inserra for performance year 2024, reported through an alternative payment model (APM). Dr. Inserra accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 22 procedures of removal of tissue by Dr. Inserra, more than 70% of the clinicians it reports for that procedure.

Dmand AI links 10 papers to Dr. Inserra, published from 2004 to 2023. The most frequent topics are Sciatic Nerve, Mice, Inbred C57BL and Nerve Regeneration. Dr. Inserra has published most often in Otol Neurotol. Dr. Inserra's most frequent co-authors are Larisa D. Kunda, MD, Charles Joseph Ballay, MD and Chrysoula Dosiou, MD.

CMS Open Payments shows 18 general payments to Dr. Inserra from 9 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Neurent Medical Limited paid the most, $201.

Dmand AI lists 1 award for Dr. Inserra, most recently CMS Stage 1 2012 in 2011.

Dr. Inserra graduated from Stanford University School Of Medicine in 1999.

Dr. Inserra is in network with 15 carriers, including Aetna, United Healthcare and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.